EA201500995A1 - Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения - Google Patents
Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их примененияInfo
- Publication number
- EA201500995A1 EA201500995A1 EA201500995A EA201500995A EA201500995A1 EA 201500995 A1 EA201500995 A1 EA 201500995A1 EA 201500995 A EA201500995 A EA 201500995A EA 201500995 A EA201500995 A EA 201500995A EA 201500995 A1 EA201500995 A1 EA 201500995A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- specific
- antibodies
- fap
- methods
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
В заявке описаны биспецифические антитела, содержащие по меньшей мере один антигенсвязывающий сайт, специфический в отношении DR5, и по меньшей мере один антигенсвязывающий сайт, специфический в отношении FAP, антитела, специфические в отношении DR5, способы их получения, фармацевтические композиции, содержащие указанные антитела, и их применения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361808128P | 2013-04-03 | 2013-04-03 | |
PCT/EP2014/056511 WO2014161845A1 (en) | 2013-04-03 | 2014-04-01 | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201500995A1 true EA201500995A1 (ru) | 2016-04-29 |
Family
ID=50397172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201500995A EA201500995A1 (ru) | 2013-04-03 | 2014-04-01 | Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения |
Country Status (26)
Country | Link |
---|---|
US (2) | US9926379B2 (ru) |
EP (1) | EP2981552B1 (ru) |
JP (2) | JP6316937B2 (ru) |
KR (2) | KR20150139909A (ru) |
CN (1) | CN105308069B (ru) |
AR (1) | AR095980A1 (ru) |
AU (1) | AU2014247175B2 (ru) |
BR (1) | BR112015025306A2 (ru) |
CA (1) | CA2903595C (ru) |
CL (2) | CL2015002829A1 (ru) |
CR (1) | CR20150502A (ru) |
EA (1) | EA201500995A1 (ru) |
ES (1) | ES2720433T3 (ru) |
HK (1) | HK1214604A1 (ru) |
IL (1) | IL241795B (ru) |
MA (1) | MA38554A3 (ru) |
MX (1) | MX370651B (ru) |
PE (1) | PE20160506A1 (ru) |
PH (1) | PH12015502293A1 (ru) |
PL (1) | PL2981552T3 (ru) |
SG (1) | SG11201508220UA (ru) |
TR (1) | TR201905458T4 (ru) |
TW (1) | TWI535736B (ru) |
UA (1) | UA118028C2 (ru) |
WO (1) | WO2014161845A1 (ru) |
ZA (1) | ZA201506471B (ru) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
EP2417156B1 (en) | 2009-04-07 | 2015-02-11 | Roche Glycart AG | Trivalent, bispecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
CN102574921B (zh) | 2009-09-29 | 2016-05-04 | 罗切格利卡特公司 | 双特异性死亡受体激动型抗体 |
SG187746A1 (en) | 2010-08-13 | 2013-03-28 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
PE20140303A1 (es) | 2011-02-10 | 2014-03-22 | Roche Glycart Ag | Polipeptidos interleuquina-2 mutantes |
ES2549638T3 (es) | 2011-02-28 | 2015-10-30 | F. Hoffmann-La Roche Ag | Proteínas de unión a antígeno |
CN103403025B (zh) | 2011-02-28 | 2016-10-12 | 弗·哈夫曼-拉罗切有限公司 | 单价抗原结合蛋白 |
KR101870555B1 (ko) | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
RU2015100656A (ru) | 2012-06-27 | 2016-08-20 | Ф. Хоффманн-Ля Рош Аг | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения |
WO2014001324A1 (en) | 2012-06-27 | 2014-01-03 | Hoffmann-La Roche Ag | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
US20160009824A1 (en) * | 2013-03-15 | 2016-01-14 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
MX2016003593A (es) | 2013-10-11 | 2016-06-02 | Hoffmann La Roche | Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico. |
JP6706578B2 (ja) | 2013-12-30 | 2020-06-10 | エピムアブ バイオセラピューティクス インコーポレイテッド | タンデム型Fab免疫グロブリン及びその使用 |
AU2015254558B2 (en) * | 2014-05-02 | 2021-02-25 | Medimmune Limited | Ion channel modulators and uses thereof |
MX2017004526A (es) * | 2014-10-08 | 2017-06-07 | Hoffmann La Roche | Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos. |
EP3224275B1 (en) | 2014-11-14 | 2020-03-04 | F.Hoffmann-La Roche Ag | Antigen binding molecules comprising a tnf family ligand trimer |
BR112017010324A2 (pt) | 2014-11-20 | 2018-05-15 | F. Hoffmann-La Roche Ag | método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula |
MX2017006571A (es) * | 2014-11-20 | 2017-09-29 | Hoffmann La Roche | Moleculas de union a antigeno biespecificas activadoras de celulas t. |
EP3227332B1 (en) | 2014-12-03 | 2019-11-06 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
BR112017011170A2 (pt) * | 2014-12-18 | 2018-02-27 | Hoffmann La Roche | método para determinar a citotoxicidade dependente do complemento de uma composição |
US20170369592A1 (en) * | 2015-01-09 | 2017-12-28 | Mabimmune Diagostics AG | Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof |
US10689449B2 (en) | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
AU2015380455A1 (en) | 2015-01-26 | 2017-08-03 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains |
WO2016156291A1 (en) | 2015-03-31 | 2016-10-06 | F. Hoffmann-La Roche Ag | Antigen binding molecules comprising a trimeric tnf family ligand |
WO2016168768A2 (en) | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
EP3112381A1 (en) * | 2015-07-01 | 2017-01-04 | FONDAZIONE IRCCS Istituto Nazionale dei Tumori | Bispecific antibodies for use in cancer immunotherapy |
CN105061604B (zh) * | 2015-08-19 | 2018-03-16 | 河南大学 | sDR5‑Fc融合蛋白突变体及其应用 |
US20180333491A1 (en) * | 2015-08-19 | 2018-11-22 | Sinotau Pharmaceuticals Group | Trail receptor-binding agents and uses of same |
CN107849122B (zh) * | 2015-08-21 | 2022-01-25 | 豪夫迈·罗氏有限公司 | 用低电导率洗涤缓冲液进行亲和层析纯化 |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
BR112018002570A2 (pt) | 2015-10-02 | 2018-10-16 | Hoffmann La Roche | molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo |
US20180363000A1 (en) * | 2015-12-14 | 2018-12-20 | The Trustees Of The University Of Pennsylvania | Aav-anti pcsk9 antibody constructs and uses thereof |
CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
CU24613B1 (es) | 2016-02-06 | 2022-07-08 | Epimab Biotherapeutics Inc | Proteínas de unión a inmunoglobulinas fabs en tandem (fit-ig) biespecíficas que se unen a cmet y egfr |
FI3433280T3 (fi) | 2016-03-22 | 2023-06-06 | Hoffmann La Roche | Proteaasin aktivoimia t-solubispesifisiä molekyylejä |
EP3231813A1 (en) * | 2016-03-29 | 2017-10-18 | F. Hoffmann-La Roche AG | Trimeric costimulatory tnf family ligand-containing antigen binding molecules |
US10202435B2 (en) | 2016-04-15 | 2019-02-12 | Alder Biopharmaceuticals, Inc. | Anti-PACAP antibodies and uses thereof |
EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
EP3243836A1 (en) * | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
EP3464367B1 (en) | 2016-05-27 | 2020-09-09 | AbbVie Biotherapeutics Inc. | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen |
EP3472614A1 (en) * | 2016-06-16 | 2019-04-24 | F. Hoffmann-La Roche AG | Assay and method for determining cdc eliciting antibodies |
RU2758007C2 (ru) | 2016-06-30 | 2021-10-25 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | 新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用 |
AU2017319318A1 (en) * | 2016-08-29 | 2019-02-21 | Tiziana Life Sciences Plc | Anti-CD3 antibody formulations |
JP7162592B2 (ja) | 2016-12-14 | 2022-10-28 | パーデュー・リサーチ・ファウンデイション | 線維芽細胞活性化タンパク質(fap)標的イメージングおよび治療 |
US11267883B2 (en) * | 2016-12-21 | 2022-03-08 | Cephalon, Inc. | Antibodies that specifically bind to human IL-15 and uses thereof |
EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
BR112019013189A2 (pt) * | 2017-01-03 | 2019-12-10 | Hoffmann La Roche | moléculas de ligação ao antígeno biespecífica, polinucleotídeo, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica, composição farmacêutica, uso, métodos para inibir o crescimento de células tumorais em um indivíduo e para tratar o câncer ou uma doença infecciosa |
US11613785B2 (en) | 2017-01-09 | 2023-03-28 | Onkosxcel Therapeutics, Llc | Predictive and diagnostic methods for prostate cancer |
BR112019017753A2 (pt) * | 2017-04-04 | 2020-04-07 | Hoffmann La Roche | molécula biespecífica, polinucleotídeo, vetor, célula, métodos para a produção de uma molécula e para o tratamento de um indivíduo, composição e uso da molécula biespecífica |
CN108997503B (zh) * | 2017-06-06 | 2021-07-23 | 深圳市中科艾深医药有限公司 | 人sDR5-Fc重组融合蛋白及其作为制备治疗生殖***炎症的药物中的应用 |
EP3710482A4 (en) * | 2017-11-14 | 2021-08-18 | University Of Virginia Patent Foundation | COMPOSITIONS AND METHODS OF MANUFACTURING AND USING BISPECIFIC ANTIBODIES |
KR102194026B1 (ko) * | 2017-12-15 | 2020-12-22 | 경북대학교 산학협력단 | Trail 수용체에 결합하는 펩타이드 및 이의 용도 |
EP3502140A1 (en) * | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
US11945839B2 (en) | 2017-12-22 | 2024-04-02 | Hoffmann-La Roche Inc. | Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography |
WO2019133847A1 (en) | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
MY198034A (en) * | 2018-12-21 | 2023-07-27 | Hoffmann La Roche | Tumor-targeted agonistic cd28 antigen binding molecules |
US20220273831A1 (en) | 2019-07-08 | 2022-09-01 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
CN114341158A (zh) | 2019-07-08 | 2022-04-12 | 3B制药有限公司 | 包含成纤维细胞活化蛋白配体的化合物及其用途 |
EP3763726A1 (en) | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
JP2022540859A (ja) * | 2019-07-12 | 2022-09-20 | リプム エービー | 新規bssl抗体 |
CN110669139A (zh) * | 2019-09-18 | 2020-01-10 | 沣潮医药科技(上海)有限公司 | 二聚体免疫粘附素、药物组合物和用途 |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
AU2021300362A1 (en) | 2020-07-01 | 2023-02-23 | ARS Pharmaceuticals, Inc. | Anti-ASGR1 antibody conjugates and uses thereof |
EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
CN116940585A (zh) | 2021-01-07 | 2023-10-24 | 3B制药有限公司 | 包含成纤维细胞活化蛋白配体的化合物及其用途 |
CN113336851B (zh) * | 2021-06-30 | 2021-12-24 | 徐州医科大学 | 新型全人源抗人b7h3抗体、包含所述抗体的组合物及其应用 |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2388385B1 (fr) | 1977-04-18 | 1982-01-08 | Hitachi Metals Ltd | Piece d'ornement fixee par des aimants permanents |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5580774A (en) | 1989-07-31 | 1996-12-03 | Eli Lilly And Company | Chimeric antibodies directed against a human glycoprotein antigen |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
AU2782292A (en) | 1991-09-18 | 1993-04-27 | Sloan-Kettering Institute For Cancer Research | Activated stromal fibroblast-specific antibody, f19 and methods of using the same |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
GB9317423D0 (en) | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6455677B1 (en) | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PRODUCING A POLYPEPTIDE |
WO2001068708A2 (en) | 2000-03-17 | 2001-09-20 | Boehringer Ingelheim Pharma Kg | Human and humanized fap-alpha-specific antibodies |
ES2528794T3 (es) | 2000-04-11 | 2015-02-12 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
DE10034607A1 (de) | 2000-07-20 | 2002-02-07 | Gundram Jung | Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren |
DE10045591A1 (de) | 2000-09-15 | 2002-04-04 | Klaus Pfizenmaier | Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2424602C (en) | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
US20020155109A1 (en) | 2001-04-20 | 2002-10-24 | Lynch David H. | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 |
NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
US7229617B2 (en) * | 2002-11-27 | 2007-06-12 | Irm Llc | Methods and compositions for inducing apoptosis in cancer cells |
DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
ES2574993T3 (es) | 2003-01-22 | 2016-06-23 | Roche Glycart Ag | Construcciones de fusión y uso de las mismas para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
EA036531B1 (ru) | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
CN1980957A (zh) | 2004-03-23 | 2007-06-13 | 比奥根艾迪克Ma公司 | 受体偶联剂及其治疗用途 |
MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
EP1791565B1 (en) | 2004-09-23 | 2016-04-20 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
SG173313A1 (en) | 2005-01-05 | 2011-08-29 | Biogen Idec Inc | Cripto binding molecules |
US8029783B2 (en) * | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
KR100847010B1 (ko) * | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (dr5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
WO2010136172A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
JP5764127B2 (ja) | 2009-08-17 | 2015-08-12 | ロシュ グリクアート アーゲー | 標的化イムノコンジュゲート |
CN102574921B (zh) | 2009-09-29 | 2016-05-04 | 罗切格利卡特公司 | 双特异性死亡受体激动型抗体 |
US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
SG187746A1 (en) * | 2010-08-13 | 2013-03-28 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
PE20140303A1 (es) | 2011-02-10 | 2014-03-22 | Roche Glycart Ag | Polipeptidos interleuquina-2 mutantes |
PT2691417T (pt) | 2011-03-29 | 2018-10-31 | Roche Glycart Ag | Variantes de fc de anticorpos |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
CN103748114B (zh) * | 2011-08-23 | 2017-07-21 | 罗切格利卡特公司 | T细胞活化性双特异性抗原结合分子 |
SI2748202T1 (sl) | 2011-08-23 | 2018-10-30 | Roche Glycart Ag | Bispecifične molekule, ki se vežejo na antigen |
BR112015002085A2 (pt) | 2012-08-08 | 2017-12-19 | Roche Glycart Ag | proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção |
UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
JP6618463B2 (ja) | 2013-05-07 | 2019-12-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 三量体型抗原結合分子 |
WO2016156291A1 (en) | 2015-03-31 | 2016-10-06 | F. Hoffmann-La Roche Ag | Antigen binding molecules comprising a trimeric tnf family ligand |
-
2014
- 2014-01-04 UA UAA201510604A patent/UA118028C2/uk unknown
- 2014-04-01 KR KR1020157031505A patent/KR20150139909A/ko active IP Right Grant
- 2014-04-01 KR KR1020177021210A patent/KR20170091179A/ko not_active Application Discontinuation
- 2014-04-01 SG SG11201508220UA patent/SG11201508220UA/en unknown
- 2014-04-01 PE PE2015002115A patent/PE20160506A1/es unknown
- 2014-04-01 EA EA201500995A patent/EA201500995A1/ru unknown
- 2014-04-01 EP EP14714275.6A patent/EP2981552B1/en not_active Not-in-force
- 2014-04-01 MA MA38554A patent/MA38554A3/fr unknown
- 2014-04-01 JP JP2016505796A patent/JP6316937B2/ja not_active Expired - Fee Related
- 2014-04-01 ES ES14714275T patent/ES2720433T3/es active Active
- 2014-04-01 WO PCT/EP2014/056511 patent/WO2014161845A1/en active Application Filing
- 2014-04-01 TR TR2019/05458T patent/TR201905458T4/tr unknown
- 2014-04-01 CA CA2903595A patent/CA2903595C/en not_active Expired - Fee Related
- 2014-04-01 US US14/231,933 patent/US9926379B2/en active Active
- 2014-04-01 AR ARP140101458A patent/AR095980A1/es unknown
- 2014-04-01 CN CN201480030231.5A patent/CN105308069B/zh not_active Expired - Fee Related
- 2014-04-01 BR BR112015025306A patent/BR112015025306A2/pt not_active IP Right Cessation
- 2014-04-01 MX MX2015013899A patent/MX370651B/es active IP Right Grant
- 2014-04-01 AU AU2014247175A patent/AU2014247175B2/en not_active Ceased
- 2014-04-01 PL PL14714275T patent/PL2981552T3/pl unknown
- 2014-04-02 TW TW103112362A patent/TWI535736B/zh not_active IP Right Cessation
-
2015
- 2015-09-03 ZA ZA2015/06471A patent/ZA201506471B/en unknown
- 2015-09-21 IL IL241795A patent/IL241795B/en not_active IP Right Cessation
- 2015-09-21 CR CR20150502A patent/CR20150502A/es unknown
- 2015-09-22 CL CL2015002829A patent/CL2015002829A1/es unknown
- 2015-10-02 PH PH12015502293A patent/PH12015502293A1/en unknown
-
2016
- 2016-03-01 HK HK16102349.6A patent/HK1214604A1/zh unknown
-
2017
- 2017-09-05 CL CL2017002244A patent/CL2017002244A1/es unknown
- 2017-10-02 JP JP2017192900A patent/JP2018046823A/ja active Pending
-
2018
- 2018-03-06 US US15/913,713 patent/US11214622B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201500995A1 (ru) | Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения | |
CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
EA202190808A2 (ru) | Составы антител к cd38 для подкожного введения и их применение | |
DK3408295T3 (da) | Farmaceutisk sammensætning, som omfatter bispecifikke antistofkonstruktioner | |
EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
EA201791139A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
EA201691974A1 (ru) | Антитела против ox40 и способы их применения | |
MX2016008098A (es) | Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso. | |
PE20210648A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
EA201600473A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
EA201401204A1 (ru) | Антитела к il-23p19 | |
EA201892509A1 (ru) | Антитела к гемагглютинину и способы применения | |
EA201490778A1 (ru) | АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ | |
EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения |